FindTrial
Sign In

HRZE

DRUG9 trials

Sponsors

Orient Pharma Co., Ltd., Global Alliance for TB Drug Development, Gates Medical Research Institute, University Hospital, Linkoeping, Indian Council of Medical Research

Conditions

Drug Sensitive TuberculosisDrug-Resistant TuberculosisPulmonary TBPulmonary TuberculosisRifampicin Susceptible Pulmonary TuberculosisTuberculosisTuberculosis MeningitisTuberculosis, MDR

Phase 2

Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis
CompletedNCT02467608
Orient Pharma Co., Ltd.Pulmonary Tuberculosis
Start: 2012-12-06End: 2019-01-09Updated: 2022-06-15
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
CompletedNCT03338621
Global Alliance for TB Drug DevelopmentDrug-Resistant Tuberculosis, Tuberculosis, Tuberculosis, MDR +2
Start: 2018-07-30End: 2022-06-10Updated: 2024-03-07
Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis
CompletedNCT04176250
Gates Medical Research InstitutePulmonary Tuberculosis
Start: 2020-01-16End: 2022-10-05Updated: 2024-04-11
Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide
SuspendedNCT04694586
University Hospital, LinkoepingTuberculosis, Pulmonary
Start: 2022-11-30End: 2026-05-31Target: 40Updated: 2024-01-05
Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis
TerminatedNCT06041919
Thirty Respiratory LimitedRifampicin Susceptible Pulmonary Tuberculosis
Start: 2023-09-27End: 2025-03-06Updated: 2025-07-15
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis
Active, not recruitingNCT06058299
Global Alliance for TB Drug DevelopmentDrug Sensitive Tuberculosis, Pulmonary TB, Pulmonary Tuberculosis
Start: 2023-10-24End: 2026-06-30Updated: 2025-02-17
A Phase 2, partially-blinded, randomised trial assessing the safety and efficacy of TBAJ876 or bedaquiline, in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis
Active, not recruitingPACTR202311505748497
TB AllianceTuberculosis
Start: 2023-09-15Target: 300Updated: 2026-01-27
Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis
Not yet recruitingNCT07350174
BioVersys AGTuberculosis Meningitis
Start: 2026-03-30End: 2028-10-30Target: 64Updated: 2026-03-03

Phase 3

Intensified Short Course Regimen for TBM in Adults
Not yet recruitingNCT05917340
Indian Council of Medical ResearchTuberculous Meningitis
Start: 2024-03-31End: 2027-09-30Target: 372Updated: 2023-12-21

Related Papers

Cardiodynamic evaluation of sorfequiline (TBAJ-876): results from a first-in-human study
Antimicrobial Agents and Chemotherapy2026-01-30
Protocol for a phase 2, partially blinded, randomized trial assessing the safety and efficacy of sorfequiline or bedaquiline in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009).
2026-01-06
Contribution of telacebec to novel drug regimens in a murine tuberculosis model
Antimicrobial Agents and Chemotherapy2024-12-094 citations
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
2024-05-1733 citations
Comparative evaluation of intensified short course regimen and standard regimen for adults TB meningitis: a protocol for an open label, multi-center, parallel arms, randomized controlled superiority trial (INSHORT trial).
2024-05-025 citations
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
BMJ Open2022-03-015 citations